Literature DB >> 11094127

Safety of pramipexole in patients with restless legs syndrome.

K Stiasny1, J C Möller, W H Oertel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11094127     DOI： 10.1212/wnl.55.10.1589

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 3.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Dopamine agonists for restless legs syndrome.

Authors:  Hanna Scholz; Claudia Trenkwalder; Ralf Kohnen; Dieter Riemann; Levente Kriston; Magdolna Hornyak
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

5.  Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes.

Authors:  William Winlow
Journal:  Core Evid       Date:  2005-03-31

6.  Pramipexole: new use for an old drug - the potential use of pramipexole in the treatment of restless legs syndrome.

Authors:  Gulcin Benbir; Christian Guilleminault
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.